Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( primate/ human) |
Target | CD23 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C2115H3252N556O673S16 |
Molar mass | 47749.46 g·mol−1 |
![]() ![]() |
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator [1] and was awarded orphan drug status and fast track designation by the FDA. [2]
It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia. [3] [4] It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens. [1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. [2] Results published from the CLL clinical trial failed to meet primary endpoints. [5]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric ( primate/ human) |
Target | CD23 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C2115H3252N556O673S16 |
Molar mass | 47749.46 g·mol−1 |
![]() ![]() |
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator [1] and was awarded orphan drug status and fast track designation by the FDA. [2]
It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia. [3] [4] It has also been studied for use in allergic asthma. The drug is a chimeric antibody from Macaca irus and Homo sapiens. [1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. [2] Results published from the CLL clinical trial failed to meet primary endpoints. [5]